GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (STU:LHI0) » Definitions » Equity-to-Asset

Algorae Pharmaceuticals (STU:LHI0) Equity-to-Asset : 0.94 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Algorae Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Algorae Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €1.45 Mil. Algorae Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was €1.53 Mil.

The historical rank and industry rank for Algorae Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

STU:LHI0' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.72   Med: 0.91   Max: 0.96
Current: 0.94

During the past 13 years, the highest Equity to Asset Ratio of Algorae Pharmaceuticals was 0.96. The lowest was 0.72. And the median was 0.91.

STU:LHI0's Equity-to-Asset is ranked better than
93.09% of 1504 companies
in the Biotechnology industry
Industry Median: 0.67 vs STU:LHI0: 0.94

Algorae Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Algorae Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Equity-to-Asset Chart

Algorae Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.84 0.94 0.89 0.94

Algorae Pharmaceuticals Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.89 0.96 0.94 0.94

Competitive Comparison of Algorae Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Algorae Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algorae Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Equity-to-Asset falls into.


;
;

Algorae Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Algorae Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Equity to Asset (A: Jun. 2024 )=Total Stockholders Equity/Total Assets
=1.859/1.97
=

Algorae Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=1.446/1.534
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algorae Pharmaceuticals  (STU:LHI0) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Algorae Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Algorae Pharmaceuticals Business Description

Traded in Other Exchanges
Address
525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals Headlines

No Headlines